Vikas Dandekar is an Editor - Pharma & Healthcare at ET Prime. With over two decades of experience tracking the Indian pharmaceutical industry, he has reported extensively on topics such as healthcare costs, pharmaceutical regulation, and the intricacies of clinical trials. Vikas has been featured in The Economic Times, where his insights into the evolving landscape of medicine and healthcare have garnered significant attention.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Vikas Dandekar's coverage is heavily focused on healthcare, pharmaceuticals, and health-related topics in India with a specific emphasis on Mumbai. It seems he would be most interested in expert commentary from professionals within the healthcare and pharmaceutical industries regarding prevailing issues such as diabetes management, heart ailments, medical research breakthroughs, and regulatory changes.
If you have expertise or insights related to these areas or can provide analysis of government announcements impacting the healthcare sector in India (especially Mumbai), your pitch may resonate well with Vikas. Additionally, if you represent an organization making significant contributions to this industry locally or nationally, it could also capture his interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Sruthijith Kk, Vikas Dandekar
Eli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and Zepbound significantly boosted the company's sales and market value. Eli Lilly sees potential in India's biotech sector, despite challenges in the research funding environment. The company is open to partnerships with Indian biotechnology firms for future collaborations.
By: Sruthijith KK, Vikas Dandekar
Eli Lilly, the worlds biggest drugmaker by market cap, plans to maintain its substantial lead in the weight-loss market with new drugs that hold promise of exceeding the success of Mounjaro and Zepbound.
By: Vikas Dandekar
In response to a laboratory worker's suspected death from bubonic plague, Russian officials have enforced quarantine protocols. Approximately 200 individuals are under watch for potential exposure to the infection, which mainly spreads via flea bites or contact with infected wildlife. Despite its serious nature, bubonic plague is treatable with antibiotics, though the pneumonic variant poses a greater threat due to its direct human transmission.
By: Vikas Dandekar
The National Formulary of India released its latest edition amidst concerns regarding unapproved drugs included in it. The Drug Controller General of India has communicated with the Indian Pharmacopoeia Commission regarding this discrepancy. Several drugs listed in NFI 2026 have not received approval from the Central Drugs Standard Control Organisation. Stakeholders have also raised complaints about the unavailability of the online version of NFI 2026.
By: Vikas Dandekar
Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push for a shift beyond generics.
Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push for a shift beyond generics
By: Vikas Dandekar
Roche highlights the urgent need for a transformation in global healthcare to effectively tackle chronic diseases. Jorg Rupp pointed out that existing healthcare infrastructures are largely reactive, falling short in proactively addressing the rise of non-communicable diseases. This burgeoning issue not only challenges health systems but also imposes heavy financial demands. Governments must begin viewing healthcare as a crucial investment aimed at enhancing health outcomes.
By: Rica Bhattacharyya
Bayer AG plans to expand its consumer health business in India significantly by 2030. The company aims to triple its revenue in the Indian market during this period. Bayer is specifically targeting opportunities in digestive health, nutrition, and multivitamins related to GLP-1 drug side effects. Additionally, Bayer will develop products locally and seek manufacturing partnerships to enhance their market presence.
By: Vikas Dandekar, Rica Bhattacharyya
For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that remain out of reach, the affordability crisis runs deep. A proposed cap may help, but question remains if it will be enough to change the picture.
Six months ago, Surekha Panicker (name changed), a 65-year-old retired professional from Kerala, stared at her diagnosis in shock—stage-2 breast cancer. She had no family and limited savings.
